DCTH

Business Context and Reporting Period

Company: Delcath Systems, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Status: Development Stage Company
Business Overview: Delcath develops the Delcath PHP System, a device for administering high-dose chemotherapy directly to the liver. The company has no commercial revenues and is focused on completing a Phase III clinical trial for metastatic melanoma and a Phase II trial for neuroendocrine and other liver cancers. As of March 31, 2009, the product has not received FDA approval.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by $1,387,735 (131%) compared to Q1 2008. This was primarily driven by a $760,029 unfavorable fluctuation in derivative instrument income/expense and increased R&D costs.
• R&D Expenses: Increased by $472,233 (48%) to $1,461,189. This reflects the expansion of the Phase III clinical trial from one center in Q1 2008 to nine centers in Q1 2009, increasing patient treatment and setup costs.
• General & Administrative (G&A): Increased by $33,960 (7.7%) to $474,964, attributed to the addition of two Board members and higher consultant fees.
• Interest Income: Decreased by $123,202 to $50,761 due to a reduced cash position and lower market interest rates.
• Cash Position: Cash and cash equivalents decreased by $2,135,091 during the quarter, resulting in a net cash outflow from operating activities of $2,335,801.

Guidance, Outlook, and Risks

• Clinical Trial Progress: The company expects to complete enrollment of 92 patients in its Phase III trial in 2009 (58 enrolled as of March 31). It also anticipates completing the neuroendocrine arm of its Phase II trial in 2009.
• Liquidity Outlook: Management believes current cash and cash equivalents ($4.8 million) are sufficient to fund operations and clinical trials through fiscal year 2009. However, the company expects capital requirements to increase as trial enrollment expands.
• Capital Needs: As a development-stage company with no revenue, Delcath will likely need to raise additional capital via equity sales, debt, or strategic alliances to continue operations beyond 2009 or to commercialize the product.
• Key Risks:
  • Regulatory Approval: The product has not received FDA approval; failure to obtain approval or delays would materially adversely affect the business.
  • Derivative Liability: The company carries a $1.01 million liability related to warrants issued in 2007, which is subject to mark-to-market adjustments. While management believes cash settlement is remote, fluctuations in stock price impact net loss.
  • Enrollment Pace: There is no assurance that patient enrollment will meet projections.

Investor Verification Checklist

• Cash Runway: Verify if the $4.8 million cash balance is sufficient to cover the accelerated burn rate associated with the expanded Phase III trial through the end of 2009.
• Derivative Liability Impact: Monitor the volatility of the stock price, as it directly impacts the quarterly net loss through mark-to-market adjustments on the $1.01 million warrant liability.
• Enrollment Milestones: Confirm the pace of patient enrollment in the Phase III trial against the 2009 completion target.
• Funding Requirements: Assess the likelihood and terms of future capital raises required post-2009, given the lack of revenue and significant accumulated deficit.
• Regulatory Status: Track FDA communications regarding the Phase III trial protocol and potential pre-market approval timelines.